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Process for the preparation of  crystalline form of 4-(4-{3-[4-chloro-3-
(trifluoromethyl)phenyl]ureido}phenoxy)N  2 -methylpyridine-2-carboxamide
A  process  for  the  preparation  of  crystalline  form  of  4-(4-{3-[4-chloro-3-
(trifluoromethyl)phenyl]ureido}phenoxy)N2-methylpyridine-2-carboxamide  compound  of
formula-I, which is represented by the following structural formula:
Formula-I
Sorafenib,  chemically  known  as  4-(4-{3-[4-chloro-3-(trifluoromethyl)
phenyl]ureido}phenoxy)N2-methylpyridine-2-carboxamide  compound  of  formula-I  and  is
approved as Sorafenib tosylate by USA & Europe under the brand name NEXAVAR® for the
treatment  of  advanced  renal  cell  carcinoma  (primary  kidney  cancer)  and  advanced
hepatocellular carcinoma (primary liver cancer). 
The present disclosure provides a process for the preparation of crystalline form of
sorafenib freebase. Dimethylsulfoxide is used to dissolve sorafenib freebase, solidified the
freebase by using aqueous methanol to obtain desired crystalline form of Sorafenib freebase.
The compound of formula-I used in the present invention is prepared by any of the 
processes known in prior art.
The following example specifies the conditions of the process for the preparation of 
crystalline sorafenib freebase.
Example: Preparation of crystalline form of Sorafenib freebase.
Sorafenib freebase (500 g) was added to the dimethylsulfoxide (900 ml) at 25-30°C
and stirred for 10 minutes at the same temperature. Heated the reaction mixture to 50-55°C
and stirred for 15 minutes at the same temperature. Filtered the reaction mixture at 50-55°C.
aqueous methanol (water 1125 ml and methanol 8750 ml) was added to the filterate at 25-
30°C.  Cooled  the  raction  mixture  to  10-15°C  and  stirred  for  60  minutes  at  the  same
temperature. Filtered the precipitated solid and washed with aqueous methanol (water 90 ml
and methanol 810 ml). obtained wet compound was added to dimethylsulfoxide (100 ml)  at
2
: Process for the preparation of crystalline form of 4-(4-{3-[4-chl
Published by Technical Disclosure Commons, 2021
25-30°C and stirred for 10 minutes at the same temperature. aqueous methanol (water 900 ml
and methanol 8100 ml) was added to the reaction mixture at 25-30°C. Cooled the reaction
mixture  to  10-15°C  and  stirred  for  60  minutes  at  the  same  temperature.  Filtered  the
precipitated solid and washed with aqueous methanol (water 90 ml and methanol 810 ml).
Dried the compound to obtain crystalline form of sorafenib freebase.
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